IDH2 and central nervous system cancer: Previous studies demonstrated that IDH1 mutations frequently occurred in grade II and III gliomas and secondary GBM glioblastoma, but rarely in primary GBM [9]; whereas IDH2 mutations occur in fewer than 3% of glial tumors.